1. Home
  2. STRO

as of 01-06-2026 3:29pm EST

$11.12
+$0.25
+2.30%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Founded: 2003 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 85.0M IPO Year: 2018
Target Price: $18.29 AVG Volume (30 days): 105.4K
Analyst Decision: Hold Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -25.88 EPS Growth: N/A
52 Week Low/High: $5.23 - $21.50 Next Earning Date: 11-06-2025
Revenue: $105,646,000 Revenue Growth: -34.36%
Revenue Growth (this year): 63.08% Revenue Growth (next year): -55.43%

AI-Powered STRO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 71.62%
71.62%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Sutro Biopharma Inc. News

STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing

All STRO News

Share on Social Networks: